EGFR and non-small cell lung carcinoma: Accumulated reports have indicated that inhibition of AKT phosphorylation simultaneously activates caspase-3 in lung cancer A549 cells32, and promotes caspase-3 resistance to EGFR inhibitor therapy in several NSCLC cell lines28.